Dose Escalation - Relapsed or refractory AML (excluding acute promyelocytic leukemia) or PDCN, based on World Health Organization Classification. All patients enrolled on this study will have CD+ disease.
Diagnosis of AML per World Health Organization (WHO) criteria (except acute promyelocytic leukemia)
Single agent (SA) Dose Escalation: Histologically or cytologically proven acute leukemia or high-risk MDS as defined by the World Health Organization (WHO) criteria and IPSS-R, respectively, that is relapsed or refractory (R/R) to standard therapy or for whom standard treatments are contraindicated, OR
Documented AML by peripheral blood or bone marrow analyses meeting World Health Organization (WHO) criteria, excluding patients with acute promyelocytic leukemia (APL)
A diagnosis of acute promyelocytic leukemia as defined by the  World Health Organization classification system
A diagnosis of recurrent, persistent, or progressive acute myelogenous leukemia (AML), defined as >= % blasts in a patient with known prior history of AML, or recurrent, persistent, or progressive myelodysplastic syndrome (MDS) according to World Health Organization (WHO) criteria
World Health Organization (WHO)-confirmed acute myeloid leukemia (AML)
Subject must have confirmation of non-acute promyelocytic leukemia (APL) AML by World Health Organization (WHO) criteria and be ineligible or unwilling to undergo treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidities or other factors
an established, confirmed diagnosis of AML by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M; and
Participant must have confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, previously untreated and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due age or comorbidities.
World Health Organization (WHO)-confirmed AML, other than acute promyelocytic leukemia (APL), with no standard treatment options available
Has a diagnosis of acute promyelocytic leukemia (APL) as defined by the World Health Organization
Participant must have histological confirmation of Acute Myeloid Leukemia (AML) by World Health Organization criteria, be ineligible for intensive induction chemotherapy and either be:
Diagnosis of untreated high-grade myeloid neoplasm (>= % myeloid blasts by morphology in bone marrow and/or peripheral blood) or AML other than acute promyelocytic leukemia (APL) with t(;)(q;q) or variants according to the  World Health Organization (WHO) classification; patients with acute leukemias of ambiguous lineage are eligible; outside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution and cytogenetic/molecular information is available
Has a diagnosis of acute promyelocytic leukemia (APL) as defined by the World Health Organization
Documented/confirmed first/second refractory/relapsed AML using World Health Organization classification, except acute promyelocytic leukemia
Must have a histopathologically documented diagnosis of primary or secondary AML (excluding acute promyelocytic leukemia), as defined by World Health Organization (WHO) criteria (Jaffe et al, ), for whom no standard therapies are anticipated to result in a durable remission according to the clinical judgment of the principal investigator, or who refuses standard therapies (phase b and ).
History of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the  World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts ?%).
Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M) with a bone marrow of >% blasts based on histology or flow cytometry
Diagnosis of untreated high-grade myeloid neoplasm (? % blasts in blood or bone marrow) or acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL) with t(;)(q;q) or variants according to the  World Health Organization (WHO) classification; outside diagnostic material is acceptable to establish diagnosis; submission of peripheral blood specimen for  flow cytometry performed at the study institution should be considered; diagnostic material must have been submitted for cytogenetic and/or molecular testing as clinically appropriate
Diagnosis of acute myeloid leukemia (AML) by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M.
A diagnosis of acute myeloid leukemia (AML) according to the World Health Organization  criteria with relapsed or refractory disease and ineligible for or have exhausted standard therapeutic options
Subjects with a prior diagnosis of AML (excluding acute promyelocytic leukemia) based on World Health Organization classification who did not achieve complete response (CR) with their previous therapy or who have relapsed after achieving a complete response (CR) are eligible; any number of relapses will be eligible
Diagnosis of acute myeloid leukemia (AML) as defined by the World Health Organization
Morphologically documented primary Acute Myeloid Leukemia (AML) or AML secondary to Myelodysplastic Syndrome (MDS), as defined by World Health Organization (WHO) criteria, as determined by pathology review at the study site.
Diagnosis of acute myelogenous leukemia (AML) according to World Health Organization (WHO) criteria;
Untreated, histological confirmed acute myeloid leukemia (AML) based on World Health Organization (WHO)  criteria with Kit expression (CD ) of myeloblasts >= % by flow cytometry from bone marrow aspirate at diagnosis
Confirmed diagnosis of non-acute promyelocytic leukemia (APL) AML (World Health Organization [WHO] criteria)
Newly diagnosed, previously untreated, cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL))
Patients must have histologically or cytologically confirmed AML, other than acute promyelocytic leukemia, as defined by the  World Health Organization (WHO) criteria that have relapsed or refractory to standard chemotherapy; unsuitable for standard chemotherapy or unwilling to undergo standard chemotherapy; subjects >=  years of age with newly diagnosed AML who are not candidates for or have refused standard chemotherapy are eligible
Patients with a new diagnosis of histologically confirmed (according to World Health Organization [WHO] classification ) acute myeloid leukemia (either primary or secondary AML) are included
Prior morphological diagnosis of AML other than acute promyelocytic leukemia according to the  World Health Organization (WHO) diagnostic criteria; patients with biphenotypic, RAS-mutated acute leukemia are also eligible
A diagnosis of acute myeloid leukemia (AML) based on World Health Organization (WHO) classification (>= % myeloblasts in peripheral blood or bone marrow)
Histologically or cytologically confirmed AML, other than acute promyelocytic leukemia, as defined by the  World Health Organization (WHO) criteria that is relapsed or refractory to standard chemotherapy; Note: newly-diagnosed AML patients who are  years or older and are not candidates for or have refused standard chemotherapy are also eligible for this trial
World Health Organization (WHO)-confirmed AML, other than acute promyelocytic leukemia (APL)
Prior diagnosis of high-risk myelodysplastic syndrome (MDS) (>= % blasts) or AML other than acute promyelocytic leukemia (APL) with t(;) (q;q) or variants according to the  World Health Organization (WHO) classification; patients with biphenotypic AML are eligible
Histologically confirmed diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) per  World Health Organization (WHO) criteria
